fig8

From: Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a

Figure 8. (A) Expression of pdk1, RXRα, PPAα, and Bcl-2 RNA was detected using RT-qPCR (^*P < 0.05, ^**P < 0.01 vs. control group); (B) The viability of U251 cells after 12 and 24 h of TMZ treatment (^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001 vs. control group); (C) The viability of U251/TMZ resistant strains after 24 h of TMZ treatment (^*P < 0.05, ^***P < 0.001, ^****P < 0.0001 vs. control group); (D) The viability of U251/TMZ resistant strains after 24 h of isocuB treatment (^*P < 0.05, ^***P < 0.001, ^****P < 0.0001 vs. control group). RT-qPCR: Reverse transcription-quantitative polymerase chain reaction; TMZ: temozolomide; isocuB: isocucurbitacin B.